In addition, the development of novel and efficient liposomal agonists, which mimic endogenous ligands and efficiently activate TREM2, has opened new avenues for TREM2-targeting drug design while demonstrating significant therapeutic potential in neuroinflammation, particularly in AD [310]. The gene discussed is TREM2; the disease is Alzheimer disease.